Generic vein health pill put to the test against Brand-Name version

NCT ID NCT07674446

Recruiting now Knowledge-focused Sponsor: Keri Pharma Hungary Kft Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This study checks whether a generic diosmin tablet (Dimotec) releases the same amount of active ingredient into the blood as the brand-name Detralex after a meal. Healthy adults aged 18 to 55 take a single dose of each tablet in random order, and blood samples are compared. The goal is to see if the two versions are bioequivalent, meaning they work the same in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Diosmin (a flavonoid used for vein health)
What this could lead to: If the two tablets are shown to be equivalent, it could offer a more affordable option for people needing diosmin therapy.
What could go wrong: This is an early-phase study in healthy volunteers, not patients. Results may not predict real-world effectiveness or safety in people with vein disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

ClinSync Clinical Research Pvt. Ltd.
RECRUITING

Hyderabad, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.